BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive: Previously, Kotschy et al. [10] showed that CML cells are relatively insensitive to S63845 treatment, possibly due to their high BCL-xL expression levels, which correlated with the resistance of hematological cancer cell lines to MCL1 inhibition.